Trial Profile

Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra) in Patients With Lenalidomide (Revlimid) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
22 Jan 2013 In order to focus its resources on the registrational programme, Telik has decided to stop further enrollment it its phase II exploratory trials, including this trial, as announced in a company media release.
22 Jan 2013 Status changed from recruiting to active, no longer recruiting based on information reported in a Telik media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com